Clinical issues and research in respiratory failure from severe acute respiratory syndrome.
暂无分享,去创建一个
Arthur S Slutsky | M. Levy | G. Bernard | G. Rubenfeld | M. Niederman | F. Hayden | S. Lapinsky | T. Stewart | R. Fowler | B. Thompson | T. Martin | T. Franks | M. Baylor | A. Harabin | R. Helfand | B. Styrt
[1] B. Murphy,et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.
[2] H. Hsieh,et al. Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by Niclosamide , 2004, Antimicrobial Agents and Chemotherapy.
[3] T. Kuiken,et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets , 2004, The Lancet.
[4] W. Sibbald,et al. Transmission of severe acute respiratory syndrome during intubation and mechanical ventilation. , 2004, American journal of respiratory and critical care medicine.
[5] Christopher W. Wong,et al. Laboratory-acquired severe acute respiratory syndrome. , 2004, The New England journal of medicine.
[6] F. Aoki,et al. Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α , 2004, The Journal of infectious diseases.
[7] Michelle M. Packard,et al. Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice , 2004, Journal of Virology.
[8] A. Debnath,et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors , 2004, The Lancet.
[9] Y. Guan,et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.
[10] Wenhui Li,et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[11] Ton de Jong,et al. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques , 2004, Nature Medicine.
[12] Peter B. Jahrling,et al. Interferon-β 1a and SARS Coronavirus Replication , 2004, Emerging infectious diseases.
[13] J. Jernigan,et al. Combining Clinical and Epidemiologic Features for Early Recognition of SARS , 2004, Emerging infectious diseases.
[14] K. Kain,et al. Severe Acute Respiratory Syndrome–associated Coronavirus in Lung Tissue , 2004, Emerging infectious diseases.
[15] J. Dennis,et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. , 2003, JAMA.
[16] G. Bernard. Corticosteroids: the "terminator" of all untreatable serious pulmonary illness. , 2003, American Journal of Respiratory and Critical Care Medicine.
[17] M. Chan-yeung,et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. , 2003, American journal of respiratory and critical care medicine.
[18] O. Tsang,et al. Coronavirus-positive Nasopharyngeal Aspirate as Predictor for Severe Acute Respiratory Syndrome Mortality , 2003, Emerging infectious diseases.
[19] P. Khong,et al. Severe acute respiratory syndrome: radiographic evaluation and clinical outcome measures. , 2003, Radiology.
[20] Elizabeth J Phillips,et al. Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] N. Adhikari,et al. A practical approach to airway management in patients with SARS. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[22] T. Stewart,et al. Communication in the Toronto critical care community: important lessons learned during SARS , 2003, Critical care.
[23] M. Peiris,et al. Infants born to mothers with severe acute respiratory syndrome. , 2003, Pediatrics.
[24] G. Boivin,et al. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. , 2003, Antiviral research.
[25] P. Hawkey,et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. , 2003, Journal of medical microbiology.
[26] H. Doerr,et al. Treatment of SARS with human interferons , 2003, The Lancet.
[27] Arul Earnest,et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. , 2003, JAMA.
[28] W. Travis,et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore , 2003, Human Pathology.
[29] G. Zeng,et al. Our strategies for fighting severe acute respiratory syndrome (SARS). , 2003, American journal of respiratory and critical care medicine.
[30] H. Doerr,et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus , 2003, The Lancet.
[31] Elizabeth Rea,et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. , 2003, JAMA.
[32] J. Peiris,et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study , 2003, The Lancet.
[33] Arthur S Slutsky,et al. Identification of severe acute respiratory syndrome in Canada. , 2003, The New England journal of medicine.
[34] Peter Cameron,et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.
[35] J. A. Comer,et al. A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[36] Michael B Edmond,et al. Managing SARS amidst uncertainty. , 2003, The New England journal of medicine.
[37] R. Maunder,et al. The immediate psychological and occupational impact of the 2003 SARS outbreak in a teaching hospital. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[38] S. Lapinsky,et al. ICU management of severe acute respiratory syndrome , 2003, Intensive Care Medicine.
[39] B. Thompson,et al. Glucocorticoids and acute lung injury , 2003, Critical care medicine.
[40] Arthur S Slutsky,et al. One-year outcomes in survivors of the acute respiratory distress syndrome. , 2003, The New England journal of medicine.
[41] S. Kaneko,et al. Synergistic antiviral effect of a combination of mouse interferon‐α and interferon‐γ on mouse hepatitis virus , 2002, Journal of medical virology.
[42] Isabelle Durand-Zaleski,et al. Paresis acquired in the intensive care unit: a prospective multicenter study. , 2002, JAMA.
[43] Darcy L Day,et al. LUNG PROTECTIVE VENTILATION (LPV) FOR ACUTE LUNG INJURY (ALI) DOES NOT INCREASE SEDATION USE: Research Citation M , 2002 .
[44] M. Niederman,et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. , 2002, Archives of internal medicine.
[45] J. Kress,et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. , 2000, The New England journal of medicine.
[46] D. Schoenfeld,et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.
[47] F. Mata,et al. Incidence of gastroesophageal reflux and aspiration in mechanically ventilated patients using small-bore nasogastric tubes. , 2000, JPEN. Journal of parenteral and enteral nutrition.
[48] G Sherman,et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. , 1999, Critical care medicine.
[49] Y. Kupfer,et al. Subcutaneous Heparin Prophylaxis Significantly Reduces The Incidence Of Venous Thromboembolic Events In The Critically Ill , 1999 .
[50] Miquel Ferrer,et al. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial , 1999, The Lancet.
[51] A. Turpie,et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.
[52] G Sherman,et al. The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. , 1998, Chest.
[53] G. Meduri,et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. , 1998, JAMA.
[54] G. Guyatt,et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. , 1998, The New England journal of medicine.
[55] M. Fine,et al. Quality of care, process, and outcomes in elderly patients with pneumonia. , 1997, JAMA.
[56] E Angus,et al. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. , 1997, Critical care medicine.
[57] H. Champion,et al. The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit. , 1996, The American surgeon.
[58] W S David,et al. Muscle weakness in mechanically ventilated patients with severe asthma. , 1996, American journal of respiratory and critical care medicine.
[59] R. Rodríguez-Roisín,et al. Semirecumbent position protects from pulmonary aspiration but not completely from gastroesophageal reflux in mechanically ventilated patients. , 1995, American journal of respiratory and critical care medicine.
[60] M. Magistris,et al. Neuromuscular disorder in intensive care unit patients treated with pancuronium bromide. Occurrence in a cluster group of seven patients and two sporadic cases, with electrophysiologic and histologic examination. , 1994, Chest.
[61] M. Lamy,et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. , 1994, American journal of respiratory and critical care medicine.
[62] J. Ibáñez,et al. Gastroesophageal reflux in intubated patients receiving enteral nutrition: effect of supine and semirecumbent positions. , 1992, JPEN. Journal of parenteral and enteral nutrition.
[63] R. Rodríguez-Roisín,et al. Pulmonary Aspiration of Gastric Contents in Patients Receiving Mechanical Ventilation: The Effect of Body Position , 1992, Annals of Internal Medicine.
[64] J. Murray,et al. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. , 1988, The American review of respiratory disease.
[65] C. Sprung,et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. , 1987, The New England journal of medicine.
[66] T. Clemmer,et al. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. , 1987, Chest.
[67] A. Meyer,et al. Sucralfate suspension versus titrated antacid for the prevention of acute stress-related gastrointestinal hemorrhage in critically ill patients , 1987 .
[68] C. Meschievitz,et al. Prevention of Experimental Coronavirus Colds with Intranasal α-2b Interferon , 1986, The Journal of infectious diseases.
[69] J. Weigelt,et al. Early steroid therapy for respiratory failure. , 1985, Archives of surgery.
[70] D. Tyrrell,et al. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers , 1983, Antimicrobial Agents and Chemotherapy.
[71] J. Cade. High risk of the critically ill for venous thromboembolism , 1982, Critical care medicine.
[72] C. Forbes,et al. Prevention of Deep Vein Thrombosis in Medical Patients by Low-Dose Heparin , 1981, Scottish medical journal.
[73] D. Matthews,et al. IN VITRO ANTIVIRAL ACTIVITY OF HUMAN RHINOVIRUS 3C PROTEASE INHIBITORS AGAINST THE SARS CORONAVIRUS , 2004 .
[74] Arthur S Slutsky,et al. Critically ill patients with severe acute respiratory syndrome. , 2003, JAMA.
[75] M. Fine,et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.